Lyn Baranowski, Chief Executive Officer and Director of Avalyn Pharma Inc., filed a Form 4 on November 19, 2026, disclosing the exercise of stock options and sale of common shares on November 17 and 18, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Trading plan: All transactions were effected under a Rule 10b5-1 plan adopted by Baranowski on July 30, 2026.
  • Options exercised: Baranowski exercised stock options covering 45,300 shares on November 17, 2026, and 7,200 shares on November 18, 2026, at an exercise price of $4.62 per share.
  • Shares sold: A total of 52,500 common shares were disposed of across five sale transactions on the two dates, at weighted average prices ranging from approximately $27.7604 to $29.2249 on November 17 and $27.9049 to $28.3643 on November 18.
  • Remaining beneficial ownership: Following all reported transactions, Baranowski held 0 shares of common stock directly, according to the filing.
  • Remaining options: After the exercises, Baranowski's directly held stock options (right to buy) totaled 610,833 shares, with an expiration date of January 24, 2034.
  • Issuer: Avalyn Pharma Inc., listed on NASDAQ:AVLN.

Baranowski Option Exercises and Share Sales at Avalyn Pharma: November 17-18, 2026

According to the filing, Lyn Baranowski exercised stock options and sold the resulting common shares over two consecutive days under a pre-established Rule 10b5-1 trading plan adopted on July 30, 2026. On November 17, 2026, Baranowski exercised options covering 45,300 shares at $4.62 per share (transaction code M). Those shares were then sold in three tranches: 39,600 shares at a weighted average price of $27.7604, 5,300 shares at a weighted average price of $28.1514, and 400 shares at a weighted average price of $29.2249, all coded as sales (S). After these transactions, the filing reports Baranowski held 0 shares directly.

On November 18, 2026, the filing discloses a second round of option exercises: 7,200 shares were acquired at $4.62 per share, then sold in two tranches - 6,465 shares at a weighted average of $27.9049 and 735 shares at a weighted average of $28.3643. The filing notes that all sale prices are weighted averages covering multiple sub-transactions, and that Baranowski will provide full per-price detail to the issuer, any security holder, or SEC staff upon request.

Regarding the underlying options, the filing states that 25% of the shares vested on October 1, 2023, with the remaining 75% vesting in thirty-six substantially equal monthly installments thereafter, subject to continued service. Following the November 18 exercise, the filing reports that Baranowski directly holds 610,833 remaining stock options with an expiration date of January 24, 2034, and an exercise price of $4.62.

What Was Disclosed

The Form 4 filed by Avalyn Pharma Inc. CEO Lyn Baranowski on November 19, 2026, discloses the exercise of stock options totaling 52,500 shares at $4.62 and the sale of all resulting shares across five transactions on November 17 and 18, 2026, under a Rule 10b5-1 plan.